News

Intractable primary CAD managed successfully with splenectomy

Splenectomy, or the surgical removal of the spleen, significantly reduced unmanageable red blood cell destruction in a man with primary cold agglutinin disease (CAD), a study showed. While this approach is usually considered to be ineffective in CAD patients, this case report adds to other studies where  CAD was successfully…

Healthy Pregnancy With AIHA Is Possible But Carries Risks: Study

Fetal complications are about four times more common in pregnant women with autoimmune hemolytic anemia (AIHA), including cold agglutinin disease (CAD), than in those without the autoimmune condition, according to a small study. Still, maternal complications occurred at similar rates, and most were directly linked to AIHA relapses, or…

Blood Transfusions With CAD, AIHAs Require Special Care: Study

Special considerations should be taken when preparing a blood transfusion for someone with cold agglutinin disease (CAD), a recent study indicates. The study, “Evaluating patients with autoimmune hemolytic anemia in the transfusion service and immunohematology reference laboratory: pretransfusion testing challenges and best transfusion-management strategies,” was published…

Report Details How CAD Patient Was Warmed for Hip Surgery

Multiple strategies to keep a woman with cold agglutinin disease (CAD) sufficiently warm right before and during hip replacement surgery allowed for a safe procedure and the absence of post-surgery complications, a case study shows. One way to reduce heat loss — and therefore prevent disease worsening — was…

Enjaymo Improves Life Quality, Lessens Fatigue: Analysis

People with cold agglutinin disease (CAD) reported clinically significant improvements in health-related quality of life after treatment with Enjaymo (sutimlimab-jome), according to a new analysis of data from the Phase 3 CADENZA clinical trial. These findings “further augment the primary efficacy outcomes of the placebo-controlled Phase 3 CADENZA…

Despite Treatment, High Unmet Medical Need in CAD, Study Finds

Even with treatment, many people with cold agglutinin disease (CAD) continue to experience moderate or severe anemia and hemolysis events caused by red blood cell destruction, a new analysis found. “Despite high proportions of patients receiving CAD-related therapies during the first year following diagnosis, the number of moderate/severe anemia…